Serum interferon-α is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis

Modern Rheumatology

Volumn 25, Issue 1, 2015, Pages 85-89

  Horai, Yoshiro ^a   Koga, Tomohiro ^a   Fujikawa, Keita ^b   Takatani, Ayuko ^a   Nishino, Ayako ^a   Nakashima, Yoshikazu ^a   Suzuki, Takahisa ^a   Kawashiri, Shin Ya ^a   Iwamoto, Naoki ^a   Ichinose, Kunihiro ^a   Tamai, Mami ^a   Nakamura, Hideki ^a   Ida, Hiroaki ^c   Kakugawa, Tomoyuki ^a   Sakamoto, Noriho ^a   Ishimatsu, Yuji ^a   Mukae, Hiroshi ^d   Hamaguchi, Yasuhito ^e   Fujimoto, Manabu ^e   Kuwana, Masataka ^f   Origuchi, Tomoki ^a   Kohno, Shigeru ^a   Kawakami, Atsushi ^a   more..

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b Isahaya Health Insurance General Hospital   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e KANAZAWA UNIVERSITY   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti MDA5 antibody; CADM; Ferritin; IFN ; RPILD

Indexed keywords

ALPHA INTERFERON; ANTIBODY; BETA INTERFERON; FERRITIN; INTERLEUKIN 18; MELANOMA DIFFERENTIATION ASSOCIATED GENE 5 ANTIBODY; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; DEAD BOX PROTEIN; IFIH1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; DERMATOMYOSITIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; PRIORITY JOURNAL; THORAX RADIOGRAPHY; AGED; BLOOD; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; AUTOANTIBODIES; BIOLOGICAL MARKERS; BIOMARKERS; DEAD-BOX RNA HELICASES; DERMATOMYOSITIS; FEMALE; FERRITINS; HUMANS; INTERFERON-ALPHA; INTERLEUKIN-18; LUNG DISEASES, INTERSTITIAL; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84946170525     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2014.900843     Document Type: Article

References (21)

1. Koenig M, Fritzler M J, Targoff IN, Troyanov Y, Senécal JL. Heterogeneity of autoantibodies in 100 patients with autoimmune myositis: insights into clinical features and outcomes. Arthritis Res Ther. 2007; 9(4): R78
2. Kameda H, Nagasawa H, Ogawa H, Sekiguchi N, Takei H, Tokuhira M, et al. Combination therapy with corticosteroids, cyclosporin A, and intravenous pulse cyclophosphamide for acute/ subacute interstitial pneumonia in patients with dermatomyositis. J Rheumatol. 2005; 32(9): 1719-1726
3. Sato S, Kuwana M. Clinically amyopathic dermatomyositis. Curr Opin Rheumatol. 2010; 22(6): 639-643
4. Sato S, Hirakata M, Kuwana M, Suwa A, Inada S, Mimori T, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum. 2005; 52(5): 1571-1576
5. Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Fujita T, Kuwana M. RNA helicase encoded by melanoma diff erentiationassociated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum. 2009; 60(7): 2193-2200
6. Takeuchi O, Akira S. M DA5/RIG-I and virus recognition. Curr Opin Immunol. 2008; 20(1): 17-22
7. Sun WC, Sun YC, Lin H, Yan B, Shi GX. Dysregulation of the type I interferon system in adult-onset clinically amyopathic dermatomyositis has a potential contribution to the development of interstitial lung disease. Br J Dermatol. 2012; 167(6): 1236-1244
8. Gono T, Sato S, Kawaguchi Y, Kuwana M, Hanaoka M, Katsumata Y, et al. Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology (Oxford). 2012; 51(9): 1563-1570
9. Gono T, Miyake K, Kawaguchi Y, Kaneko H, Shinozaki M, Yamanaka H. Hyperferritinaemia and macrophage activation in a patient with interstitial lung disease with clinically amyopathic DM. Rheumatology (Oxford). 2012; 51(7): 1336-1338
10. Gono T, Kawaguchi Y, Sugiura T, Ichida H, Takagi K, Katsumata Y, et al. Interleukin-18 is a key mediator in dermatomyositis: potential contribution to development of interstitial lung disease. Rheumatology (Oxford). 2010; 49(10): 1878-1881
11. Bohan A, Peter J B. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975; 292(7): 344-347
12. Bohan A, Peter J B. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975; 292(8): 403-407
13. Sontheimer RD. Would a new name hasten the acceptance of amyopathic dermatomyositis (dermatomyositis sinémyositis) as a distinctive subset within the idiopathic infl ammatory dermatomyopathies spectrum of clinical illness? J Am Acad Dermatol. 2002; 46(4): 626-36
14. K oga T, F ujikawa K, H orai Y, O kada A, K awashiri S Y, Iwamoto N, et al. The diagnostic utility of anti-melanoma diff erentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford). 2012; 51(7): 1278-1284
15. Cao H, Pan M, Kang Y, Xia Q, Li X, Zhao X, et al. Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of anti-melanoma diff erentiation-associated gene 5 antibody. Arthritis Care Res (Hoboken). 2012; 64(10): 1602-1610
16. Gong X, Zhou J, Zhu W, Liu N, Li J, Li L, et al. Excessive proinfl ammatory cytokine and chemokine responses of human monocyte-derived macrophages to enterovirus 71 infection. BMC Infect Dis. 2012; 12(9): 224
17. Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest. 2002; 32 Suppl 1: 79-83
18. Tucci M, Quatraro C, Dammacco F, Silvestris F. Increased IL-18 production by dendritic cells in active inflammatory myopathies. Ann N Y Acad Sci. 2007 June; 1107: 184-192
19. Greenberg S A. D ermatomyositis and type 1 interferons. Curr Rheumatol Rep. 2012; 12(3): 198-203
20. Kró P, Kryštůfková O, Polanská M, Mann H, Klein M, Beran O, et al. Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis. 2010; 70(5): 879-880
21. Fujikawa K, Kawakami A, Kaji K, Fujimoto M, Kawashiri S, Iwamoto N, et al. Association of distinct clinical subsets with myositis-specifi c autoantibodies towards anti-155/140-kDa polypeptides, anti-140-kDa polypeptides, and anti-aminoacyl tRNA synthetases in Japanese patients with dermatomyositis: a singlecentre, cross-sectional study. Scand J Rheumatol. 2009; 38(4): 263-267.